Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986511 in Adults with Major Depressive Disorder
NCT07772531Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2026
- Primary completion
- Nov 2028
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of evifacotrep in major depressive disorder (MDD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Hamilton Depression Rating Scale -17 Item total score at Day 57. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
evifacotrep
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07772531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07772531.